Safety and Tolerability of IBI355 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

February 26, 2025

Study Completion Date

April 2, 2025

Conditions

Healthy

Interventions

DRUG

placebo

IBI355 7.5mg/kg Q4W

DRUG

IBI355

IBI355 1mg/kg Q4W

Trial Locations (1)

Aerospace Center Hospital, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06416787 - Safety and Tolerability of IBI355 in Healthy Volunteers | Biotech Hunter | Biotech Hunter